ID   TPM3_HUMAN              Reviewed;         285 AA.
AC   P06753; D3DV71; P12324; Q2QD06; Q5VU58; Q5VU63; Q5VU66; Q5VU71; Q5VU72;
AC   Q8TCG3; Q969Q2; Q9NQH8;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   26-JUN-2013, sequence version 2.
DT   18-JUN-2025, entry version 252.
DE   RecName: Full=Tropomyosin alpha-3 chain;
DE   AltName: Full=Gamma-tropomyosin;
DE   AltName: Full=Tropomyosin-3;
DE   AltName: Full=Tropomyosin-5;
DE            Short=hTM5;
GN   Name=TPM3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3018581; DOI=10.1038/322648a0;
RA   Reinach F.C., McLeod A.R.;
RT   "Tissue-specific expression of the human tropomyosin gene involved in the
RT   generation of the trk oncogene.";
RL   Nature 322:648-650(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=3024106; DOI=10.1093/nar/14.21.8413;
RA   McLeod A.R., Houlker C., Talbot K.;
RT   "The mRNA and RNA-copy pseudogenes encoding TM30nm, a human cytoskeletal
RT   tropomyosin.";
RL   Nucleic Acids Res. 14:8413-8426(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE (ISOFORMS 1 AND 2).
RX   PubMed=3418707; DOI=10.1016/0022-2836(88)90633-x;
RA   Clayton L., Reinach F.C., Chumbley G.M., MacLeod A.R.;
RT   "Organization of the hTMnm gene. Implications for the evolution of muscle
RT   and non-muscle tropomyosins.";
RL   J. Mol. Biol. 201:507-515(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 3).
RC   TISSUE=Colon cancer;
RA   Lin J.J.-C., Lin J.L.-C., Geng X., Das K.M.;
RT   "Identification and characterization of a novel tropomyosin isoform from a
RT   colon cancer cell line T84.";
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Bone, Kidney, Skeletal muscle, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 2-248 (ISOFORM 2), AND IDENTIFICATION
RP   OF RCTPM3.
RX   PubMed=16201836; DOI=10.1371/journal.pbio.0030357;
RA   Marques A.C., Dupanloup I., Vinckenbosch N., Reymond A., Kaessmann H.;
RT   "Emergence of young human genes after a burst of retroposition in
RT   primates.";
RL   PLoS Biol. 3:E357-E357(2005).
RN   [9]
RP   PROTEIN SEQUENCE OF 93-126; 135-150; 154-168 AND 215-245, PARTIAL PROTEIN
RP   SEQUENCE (ISOFORMS 2/3), CLEAVAGE OF INITIATOR METHIONINE (ISOFORMS 2/3),
RP   ACETYLATION AT ALA-2 (ISOFORMS 2/3), AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=B-cell lymphoma, and Platelet;
RA   Bienvenut W.V., Claeys D.;
RL   Submitted (DEC-2005) to UniProtKB.
RN   [10]
RP   PROTEIN SEQUENCE OF 93-119, PARTIAL PROTEIN SEQUENCE (ISOFORMS 2/3),
RP   CLEAVAGE OF INITIATOR METHIONINE (ISOFORMS 2/3), ACETYLATION AT ALA-2
RP   (ISOFORMS 2/3), AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Osteosarcoma;
RA   Bienvenut W.V., Glen H., Brunton V.G., Frame M.C.;
RL   Submitted (JUL-2007) to UniProtKB.
RN   [11]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND CHROMOSOMAL
RP   TRANSLOCATION WITH NTRK1.
RX   PubMed=2869410; DOI=10.1038/319743a0;
RA   Martin-Zanca D., Hughes S.H., Barbacid M.;
RT   "A human oncogene formed by the fusion of truncated tropomyosin and protein
RT   tyrosine kinase sequences.";
RL   Nature 319:743-748(1986).
RN   [12]
RP   PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Keratinocyte;
RX   PubMed=1286667; DOI=10.1002/elps.11501301199;
RA   Rasmussen H.H., van Damme J., Puype M., Gesser B., Celis J.E.,
RA   Vandekerckhove J.;
RT   "Microsequences of 145 proteins recorded in the two-dimensional gel protein
RT   database of normal human epidermal keratinocytes.";
RL   Electrophoresis 13:960-969(1992).
RN   [13]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6).
RC   TISSUE=Skeletal muscle;
RX   PubMed=12574106; DOI=10.1161/01.hyp.0000050646.79785.7c;
RA   Dunn S.A., Mohteshamzadeh M., Daly A.K., Thomas T.H.;
RT   "Altered tropomyosin expression in essential hypertension.";
RL   Hypertension 41:347-354(2003).
RN   [14]
RP   INTERACTION WITH TMOD1.
RX   PubMed=8002995; DOI=10.1006/bbrc.1994.1747;
RA   Sung L.A., Lin J.J.-C.;
RT   "Erythrocyte tropomodulin binds to the N-terminus of hTM5, a tropomyosin
RT   isoform encoded by the gamma-tropomyosin gene.";
RL   Biochem. Biophys. Res. Commun. 201:627-634(1994).
RN   [15]
RP   IDENTIFICATION OF RCTPM3 BY MASS SPECTROMETRY.
RC   TISSUE=Mammary cancer;
RA   Ahamed M.E., Ahmed M.E., Eltoum A.M., Altahir G.O., Ahmed K.M., Harbi S.O.,
RA   Stansalas J., Mohamed A.O.;
RT   "Abnormal proteins in primary breast cancer tissues from 25 Sudanese
RT   patients.";
RL   Eur. J. Inflamm. 6:115-121(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-177 (ISOFORMS 2; 3 AND 6),
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-215 (ISOFORMS 2 AND 5),
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-125 (ISOFORM 7), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-88, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [22]
RP   INTERACTION WITH TNNT1.
RX   PubMed=35510366; DOI=10.1002/humu.24397;
RA   Holling T., Lisfeld J., Johannsen J., Matschke J., Song F., Altmeppen H.C.,
RA   Kutsche K.;
RT   "Autosomal dominantly inherited myopathy likely caused by the TNNT1 variant
RT   p.(Asp65Ala).";
RL   Hum. Mutat. 43:1224-1233(2022).
RN   [23]
RP   VARIANT CMYO4A ARG-9.
RX   PubMed=7704029; DOI=10.1038/ng0195-75;
RA   Laing N.G., Wilton S.D., Akkari P.A., Dorosz S., Boundy K., Kneebone C.,
RA   Blumbergs P., White S., Watkins H., Love D.R., Haan E.;
RT   "A mutation in the alpha tropomyosin gene TPM3 associated with autosomal
RT   dominant nemaline myopathy.";
RL   Nat. Genet. 9:75-79(1995).
RN   [24]
RP   ERRATUM OF PUBMED:7704029.
RX   PubMed=7663526; DOI=10.1038/ng0695-249;
RA   Laing N.G., Wilton S.D., Akkari P.A., Dorosz S., Boundy K., Kneebone C.,
RA   Blumbergs P., White S., Watkins H., Love D.R., Haan E.;
RL   Nat. Genet. 10:249-249(1995).
RN   [25]
RP   CHARACTERIZATION OF VARIANT CMYO4A ARG-9.
RX   PubMed=10587521; DOI=10.1172/jci7842;
RA   Michele D.E., Albayya F.P., Metzger J.M.;
RT   "A nemaline myopathy mutation in alpha-tropomyosin causes defective
RT   regulation of striated muscle force production.";
RL   J. Clin. Invest. 104:1575-1581(1999).
RN   [26]
RP   VARIANT CMYO4A HIS-168.
RX   PubMed=17376686; DOI=10.1016/j.nmd.2007.01.017;
RA   Penisson-Besnier I., Monnier N., Toutain A., Dubas F., Laing N.;
RT   "A second pedigree with autosomal dominant nemaline myopathy caused by TPM3
RT   mutation: a clinical and pathological study.";
RL   Neuromuscul. Disord. 17:330-337(2007).
RN   [27]
RP   VARIANTS CMYO4A MET-100; CYS-168; GLY-168; HIS-168; GLU-169 AND GLY-245.
RX   PubMed=18300303; DOI=10.1002/ana.21308;
RA   Clarke N.F., Kolski H., Dye D.E., Lim E., Smith R.L., Patel R., Fahey M.C.,
RA   Bellance R., Romero N.B., Johnson E.S., Labarre-Vila A., Monnier N.,
RA   Laing N.G., North K.N.;
RT   "Mutations in TPM3 are a common cause of congenital fiber type
RT   disproportion.";
RL   Ann. Neurol. 63:329-337(2008).
RN   [28]
RP   INVOLVEMENT IN CMYO4B.
RX   PubMed=18382475; DOI=10.1038/ejhg.2008.60;
RA   Lehtokari V.L., Pelin K., Donner K., Voit T., Rudnik-Schoeneborn S.,
RA   Stoetter M., Talim B., Topaloglu H., Laing N.G., Wallgren-Pettersson C.;
RT   "Identification of a founder mutation in TPM3 in nemaline myopathy patients
RT   of Turkish origin.";
RL   Eur. J. Hum. Genet. 16:1055-1061(2008).
RN   [29]
RP   VARIANT CMYO4A CYS-168.
RX   PubMed=19487656; DOI=10.1212/wnl.0b013e3181a82659;
RA   Ohlsson M., Fidzianska A., Tajsharghi H., Oldfors A.;
RT   "TPM3 mutation in one of the original cases of cap disease.";
RL   Neurology 72:1961-1963(2009).
RN   [30]
RP   VARIANT CMYO4A HIS-168.
RX   PubMed=19553118; DOI=10.1016/j.nmd.2009.06.365;
RA   De Paula A.M., Franques J., Fernandez C., Monnier N., Lunardi J.,
RA   Pellissier J.F., Figarella-Branger D., Pouget J.;
RT   "A TPM3 mutation causing cap myopathy.";
RL   Neuromuscul. Disord. 19:685-688(2009).
RN   [31]
RP   VARIANTS CMYO4A VAL-4; PRO-91; HIS-168 AND LYS-241.
RX   PubMed=19953533; DOI=10.1002/humu.21157;
RA   Lawlor M.W., Dechene E.T., Roumm E., Geggel A.S., Moghadaszadeh B.,
RA   Beggs A.H.;
RT   "Mutations of tropomyosin 3 (TPM3) are common and associated with type 1
RT   myofiber hypotrophy in congenital fiber type disproportion.";
RL   Hum. Mutat. 31:176-183(2010).
RN   [32]
RP   VARIANTS CMYO4A HIS-168 AND ALA-174.
RX   PubMed=20951040; DOI=10.1016/j.nmd.2010.07.274;
RA   Munot P., Lashley D., Jungbluth H., Feng L., Pitt M., Robb S.A., Palace J.,
RA   Jayawant S., Kennet R., Beeson D., Cullup T., Abbs S., Laing N., Sewry C.,
RA   Muntoni F.;
RT   "Congenital fibre type disproportion associated with mutations in the
RT   tropomyosin 3 (TPM3) gene mimicking congenital myasthenia.";
RL   Neuromuscul. Disord. 20:796-800(2010).
RN   [33]
RP   VARIANTS CMYO4A PHE-88; VAL-100; ALA-151; CYS-168; HIS-168 AND ILE-245, AND
RP   VARIANTS CYS-91 AND LYS-253.
RX   PubMed=24692096; DOI=10.1002/humu.22554;
RA   Marttila M., Lehtokari V.L., Marston S., Nyman T.A., Barnerias C.,
RA   Beggs A.H., Bertini E., Ceyhan-Birsoy O., Cintas P., Gerard M.,
RA   Gilbert-Dussardier B., Hogue J.S., Longman C., Eymard B., Frydman M.,
RA   Kang P.B., Klinge L., Kolski H., Lochmueller H., Magy L., Manel V.,
RA   Mayer M., Mercuri E., North K.N., Peudenier-Robert S., Pihko H.,
RA   Probst F.J., Reisin R., Stewart W., Taratuto A.L., de Visser M.,
RA   Wilichowski E., Winer J., Nowak K., Laing N.G., Winder T.L., Monnier N.,
RA   Clarke N.F., Pelin K., Groenholm M., Wallgren-Pettersson C.;
RT   "Mutation update and genotype-phenotype correlations of novel and
RT   previously described mutations in TPM2 and TPM3 causing congenital
RT   myopathies.";
RL   Hum. Mutat. 35:779-790(2014).
RN   [34]
RP   VARIANT CMYO4A ILE-149.
RX   PubMed=24239060; DOI=10.1016/j.nmd.2013.10.002;
RA   Schreckenbach T., Schroeder J.M., Voit T., Abicht A., Neuen-Jacob E.,
RA   Roos A., Bulst S., Kuhl C., Schulz J.B., Weis J., Claeys K.G.;
RT   "Novel TPM3 mutation in a family with cap myopathy and review of the
RT   literature.";
RL   Neuromuscul. Disord. 24:117-124(2014).
CC   -!- FUNCTION: Binds to actin filaments in muscle and non-muscle cells.
CC       Plays a central role, in association with the troponin complex, in the
CC       calcium dependent regulation of vertebrate striated muscle contraction.
CC       Smooth muscle contraction is regulated by interaction with caldesmon.
CC       In non-muscle cells is implicated in stabilizing cytoskeleton actin
CC       filaments. {ECO:0000250|UniProtKB:P09493}.
CC   -!- SUBUNIT: Homodimer. Heterodimer of an alpha (TPM1, TPM3 or TPM4) and a
CC       beta (TPM2) chain (By similarity). Interacts with TMOD1
CC       (PubMed:8002995). Interacts with TNNT1 (PubMed:35510366).
CC       {ECO:0000250|UniProtKB:P04692, ECO:0000269|PubMed:35510366,
CC       ECO:0000269|PubMed:8002995}.
CC   -!- INTERACTION:
CC       P06753; P54253: ATXN1; NbExp=4; IntAct=EBI-355607, EBI-930964;
CC       P06753; Q8TAB5: C1orf216; NbExp=4; IntAct=EBI-355607, EBI-747505;
CC       P06753; Q969G5: CAVIN3; NbExp=4; IntAct=EBI-355607, EBI-3893101;
CC       P06753; Q8TD31-3: CCHCR1; NbExp=13; IntAct=EBI-355607, EBI-10175300;
CC       P06753; Q8IZT9: FAM9C; NbExp=8; IntAct=EBI-355607, EBI-2870039;
CC       P06753; P02671-2: FGA; NbExp=3; IntAct=EBI-355607, EBI-9640259;
CC       P06753; Q03933: HSF2; NbExp=10; IntAct=EBI-355607, EBI-2556750;
CC       P06753; Q9ULV5-2: HSF4; NbExp=3; IntAct=EBI-355607, EBI-12056251;
CC       P06753; O14879: IFIT3; NbExp=5; IntAct=EBI-355607, EBI-745127;
CC       P06753; Q9BQD3: KXD1; NbExp=13; IntAct=EBI-355607, EBI-739657;
CC       P06753; O95447: LCA5L; NbExp=4; IntAct=EBI-355607, EBI-8473670;
CC       P06753; Q96LR2: LURAP1; NbExp=4; IntAct=EBI-355607, EBI-741355;
CC       P06753; Q9Y6D9: MAD1L1; NbExp=10; IntAct=EBI-355607, EBI-742610;
CC       P06753; Q7Z3B4: NUP54; NbExp=6; IntAct=EBI-355607, EBI-741048;
CC       P06753; O43482: OIP5; NbExp=12; IntAct=EBI-355607, EBI-536879;
CC       P06753; Q6NSJ2-2: PHLDB3; NbExp=3; IntAct=EBI-355607, EBI-11018958;
CC       P06753; P62195: PSMC5; NbExp=3; IntAct=EBI-355607, EBI-357745;
CC       P06753; O95295: SNAPIN; NbExp=3; IntAct=EBI-355607, EBI-296723;
CC       P06753; Q8N0S2: SYCE1; NbExp=7; IntAct=EBI-355607, EBI-6872807;
CC       P06753; Q9NYJ8: TAB2; NbExp=3; IntAct=EBI-355607, EBI-358708;
CC       P06753; P0C1Z6: TFPT; NbExp=14; IntAct=EBI-355607, EBI-1245626;
CC       P06753; P0C1Z6-2: TFPT; NbExp=3; IntAct=EBI-355607, EBI-10178002;
CC       P06753; Q9NVV9: THAP1; NbExp=6; IntAct=EBI-355607, EBI-741515;
CC       P06753; Q9BT49: THAP7; NbExp=3; IntAct=EBI-355607, EBI-741350;
CC       P06753; P19237: TNNI1; NbExp=3; IntAct=EBI-355607, EBI-746692;
CC       P06753; P13805-3: TNNT1; NbExp=3; IntAct=EBI-355607, EBI-12151635;
CC       P06753; P67936: TPM4; NbExp=5; IntAct=EBI-355607, EBI-1642100;
CC       P06753; Q9UJT2: TSKS; NbExp=3; IntAct=EBI-355607, EBI-852101;
CC       P06753; Q8N1B4: VPS52; NbExp=3; IntAct=EBI-355607, EBI-2799833;
CC       P06753-2; Q86V38: ATN1; NbExp=3; IntAct=EBI-10977875, EBI-11954292;
CC       P06753-2; P54253: ATXN1; NbExp=3; IntAct=EBI-10977875, EBI-930964;
CC       P06753-2; Q9Y5Z0: BACE2; NbExp=3; IntAct=EBI-10977875, EBI-11282723;
CC       P06753-2; Q92876: KLK6; NbExp=3; IntAct=EBI-10977875, EBI-2432309;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1; Synonyms=Skeletal muscle;
CC         IsoId=P06753-1; Sequence=Displayed;
CC       Name=2; Synonyms=Cytoskeletal, TM30nm;
CC         IsoId=P06753-2; Sequence=VSP_006604, VSP_006605, VSP_006606;
CC       Name=3;
CC         IsoId=P06753-3; Sequence=VSP_006604, VSP_006605, VSP_006607;
CC       Name=4;
CC         IsoId=P06753-4; Sequence=VSP_047302, VSP_047303, VSP_047304,
CC                                  VSP_047305, VSP_047306;
CC       Name=5;
CC         IsoId=P06753-5; Sequence=VSP_047302, VSP_047303, VSP_047304,
CC                                  VSP_006606;
CC       Name=6;
CC         IsoId=P06753-6; Sequence=VSP_006604, VSP_006605;
CC       Name=7;
CC         IsoId=P06753-7; Sequence=VSP_054792, VSP_006606;
CC   -!- DOMAIN: The molecule is in a coiled coil structure that is formed by 2
CC       polypeptide chains. The sequence exhibits a prominent seven-residues
CC       periodicity.
CC   -!- DISEASE: Congenital myopathy 4A, autosomal dominant (CMYO4A)
CC       [MIM:255310]: A muscular disorder characterized by onset of muscle
CC       weakness in infancy or childhood. Most affected individuals show mildly
CC       delayed motor development, hypotonia, generalized muscle weakness, and
CC       weakness of the proximal limb muscles and neck muscles, resulting in
CC       difficulty running and easy fatigability. Many patients have
CC       respiratory insufficiency with reduced vital capacity. Skeletal muscle
CC       biopsy shows nemaline rod inclusions, subsarcolemmal 'cap' structures,
CC       and fiber-type disproportion. {ECO:0000269|PubMed:10587521,
CC       ECO:0000269|PubMed:17376686, ECO:0000269|PubMed:18300303,
CC       ECO:0000269|PubMed:19487656, ECO:0000269|PubMed:19553118,
CC       ECO:0000269|PubMed:19953533, ECO:0000269|PubMed:20951040,
CC       ECO:0000269|PubMed:24239060, ECO:0000269|PubMed:24692096,
CC       ECO:0000269|PubMed:7704029}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Congenital myopathy 4B, autosomal recessive (CMYO4B)
CC       [MIM:609284]: A muscular disorder characterized by muscle weakness
CC       appearing in infancy or early childhood. Most affected individuals show
CC       congenital contractures, delayed motor development, hypotonia,
CC       respiratory insufficiency, generalized muscle weakness, and weakness of
CC       the proximal limb muscles and neck muscles, resulting in difficulty
CC       walking or inability to walk. Skeletal muscle biopsy shows variable
CC       histologic findings, including nemaline rods, type 1 fiber
CC       predomination, and centralized nuclei. {ECO:0000269|PubMed:18382475}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Note=A chromosomal aberration involving TPM3 is found in
CC       papillary thyroid carcinomas (PTCs). A rearrangement with NTRK1
CC       generates the TRK fusion transcript by fusing the amino end of isoform
CC       2 of TPM3 to the 3'-end of NTRK1. {ECO:0000269|PubMed:2869410}.
CC   -!- MISCELLANEOUS: [Isoform 2]: Peptides 2-27, 41-55, 132-153, 163-169,
CC       216-225 and 237-248 have been identified and sequenced by MS.
CC       PubMed:16201836 (ABC40673) sequence corresponds to a TPM3 retrocopy
CC       (rcTPM3) on chromosome 16 that is generated by retroposition of
CC       reversed transcribed mRNA back to the genome. rcTPM3 functionality is
CC       uncertain. It has been detected by MS in primary breast cancer tissues.
CC       {ECO:0000269|Ref.10, ECO:0000269|Ref.9, ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Peptides 2-27, 41-55, 132-153 and 163-169
CC       have been identified and sequenced by MS. {ECO:0000269|Ref.10,
CC       ECO:0000269|Ref.9, ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the tropomyosin family. {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-2 is the initiator.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/225/TPM3";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X04201; CAA27798.1; -; mRNA.
DR   EMBL; AY004867; AAF87083.1; -; mRNA.
DR   EMBL; X04588; CAB37185.1; -; mRNA.
DR   EMBL; AL590431; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471121; EAW53229.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW53230.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW53231.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW53235.1; -; Genomic_DNA.
DR   EMBL; BC000771; AAH00771.1; -; mRNA.
DR   EMBL; BC008407; AAH08407.1; -; mRNA.
DR   EMBL; BC008425; AAH08425.1; -; mRNA.
DR   EMBL; BC015403; AAH15403.1; -; mRNA.
DR   EMBL; BC072428; AAH72428.1; -; mRNA.
DR   EMBL; DQ120714; ABC40673.1; -; Genomic_DNA.
DR   EMBL; X03541; CAA27243.1; ALT_TERM; mRNA.
DR   EMBL; AF474157; AAL84570.1; -; mRNA.
DR   CCDS; CCDS1060.1; -. [P06753-2]
DR   CCDS; CCDS41400.1; -. [P06753-5]
DR   CCDS; CCDS41401.1; -. [P06753-4]
DR   CCDS; CCDS41402.1; -. [P06753-3]
DR   CCDS; CCDS41403.1; -. [P06753-1]
DR   CCDS; CCDS60274.1; -. [P06753-7]
DR   CCDS; CCDS60275.1; -. [P06753-6]
DR   PIR; A25530; A25530.
DR   PIR; S06210; A24199.
DR   RefSeq; NP_001036816.1; NM_001043351.2. [P06753-5]
DR   RefSeq; NP_001036817.1; NM_001043352.2. [P06753-3]
DR   RefSeq; NP_001036818.1; NM_001043353.2. [P06753-4]
DR   RefSeq; NP_001265118.1; NM_001278189.2. [P06753-6]
DR   RefSeq; NP_001265120.1; NM_001278191.2. [P06753-7]
DR   RefSeq; NP_001351612.1; NM_001364683.1. [P06753-6]
DR   RefSeq; NP_689476.2; NM_152263.4. [P06753-1]
DR   RefSeq; NP_705935.1; NM_153649.4. [P06753-2]
DR   PDB; 6OTN; X-ray; 2.40 A; A/B/C/D=44-117.
DR   PDBsum; 6OTN; -.
DR   AlphaFoldDB; P06753; -.
DR   SMR; P06753; -.
DR   BioGRID; 113023; 399.
DR   CORUM; P06753; -.
DR   FunCoup; P06753; 1064.
DR   IntAct; P06753; 169.
DR   MINT; P06753; -.
DR   STRING; 9606.ENSP00000498577; -.
DR   ChEMBL; CHEMBL3804747; -.
DR   DrugBank; DB12695; Phenethyl Isothiocyanate.
DR   GlyGen; P06753; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P06753; -.
DR   MetOSite; P06753; -.
DR   PhosphoSitePlus; P06753; -.
DR   SwissPalm; P06753; -.
DR   BioMuta; TPM3; -.
DR   DMDM; 519668659; -.
DR   jPOST; P06753; -.
DR   MassIVE; P06753; -.
DR   PaxDb; 9606-ENSP00000357516; -.
DR   PeptideAtlas; P06753; -.
DR   ProteomicsDB; 51930; -. [P06753-1]
DR   ProteomicsDB; 51931; -. [P06753-2]
DR   ProteomicsDB; 51932; -. [P06753-3]
DR   ProteomicsDB; 65387; -.
DR   ProteomicsDB; 65390; -.
DR   ProteomicsDB; 65392; -.
DR   ProteomicsDB; 65394; -.
DR   Pumba; P06753; -.
DR   Antibodypedia; 1682; 232 antibodies from 33 providers.
DR   DNASU; 7170; -.
DR   Ensembl; ENST00000302206.9; ENSP00000307712.5; ENSG00000143549.22. [P06753-7]
DR   Ensembl; ENST00000323144.12; ENSP00000357518.4; ENSG00000143549.22. [P06753-4]
DR   Ensembl; ENST00000328159.9; ENSP00000357520.1; ENSG00000143549.22. [P06753-6]
DR   Ensembl; ENST00000330188.13; ENSP00000339035.7; ENSG00000143549.22. [P06753-5]
DR   Ensembl; ENST00000341485.10; ENSP00000341653.6; ENSG00000143549.22. [P06753-4]
DR   Ensembl; ENST00000368531.6; ENSP00000357517.2; ENSG00000143549.22. [P06753-3]
DR   Ensembl; ENST00000368533.8; ENSP00000357521.3; ENSG00000143549.22. [P06753-2]
DR   Ensembl; ENST00000651641.1; ENSP00000498577.1; ENSG00000143549.22. [P06753-1]
DR   GeneID; 7170; -.
DR   KEGG; hsa:7170; -.
DR   MANE-Select; ENST00000651641.1; ENSP00000498577.1; NM_152263.4; NP_689476.2.
DR   UCSC; uc001fdy.2; human. [P06753-1]
DR   AGR; HGNC:12012; -.
DR   CTD; 7170; -.
DR   DisGeNET; 7170; -.
DR   GeneCards; TPM3; -.
DR   HGNC; HGNC:12012; TPM3.
DR   HPA; ENSG00000143549; Group enriched (skeletal muscle, tongue).
DR   MalaCards; TPM3; -.
DR   MIM; 164970; gene.
DR   MIM; 191030; gene.
DR   MIM; 255310; phenotype.
DR   MIM; 609284; phenotype.
DR   OpenTargets; ENSG00000143549; -.
DR   Orphanet; 171881; Cap myopathy.
DR   Orphanet; 171439; Childhood-onset nemaline myopathy.
DR   Orphanet; 2020; Congenital fiber-type disproportion myopathy.
DR   Orphanet; 476406; Congenital generalized hypercontractile muscle stiffness syndrome.
DR   Orphanet; 178342; Inflammatory myofibroblastic tumor.
DR   Orphanet; 171433; Intermediate nemaline myopathy.
DR   VEuPathDB; HostDB:ENSG00000143549; -.
DR   eggNOG; KOG1003; Eukaryota.
DR   GeneTree; ENSGT01030000234542; -.
DR   HOGENOM; CLU_055027_3_0_1; -.
DR   InParanoid; P06753; -.
DR   OMA; EKKAADX; -.
DR   OrthoDB; 128924at2759; -.
DR   PAN-GO; P06753; 4 GO annotations based on evolutionary models.
DR   PhylomeDB; P06753; -.
DR   PathwayCommons; P06753; -.
DR   Reactome; R-HSA-390522; Striated Muscle Contraction.
DR   Reactome; R-HSA-445355; Smooth Muscle Contraction.
DR   Reactome; R-HSA-9013424; RHOV GTPase cycle.
DR   Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants.
DR   SignaLink; P06753; -.
DR   SIGNOR; P06753; -.
DR   BioGRID-ORCS; 7170; 15 hits in 1152 CRISPR screens.
DR   CD-CODE; DEE660B4; Stress granule.
DR   CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities.
DR   ChiTaRS; TPM3; human.
DR   GeneWiki; Tropomyosin_3; -.
DR   GenomeRNAi; 7170; -.
DR   Pharos; P06753; Tbio.
DR   PRO; PR:P06753; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P06753; protein.
DR   Bgee; ENSG00000143549; Expressed in hindlimb stylopod muscle and 154 other cell types or tissues.
DR   ExpressionAtlas; P06753; baseline and differential.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:HPA.
DR   GO; GO:0005884; C:actin filament; IBA:GO_Central.
DR   GO; GO:0005856; C:cytoskeleton; TAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; HTP:FlyBase.
DR   GO; GO:0005862; C:muscle thin filament tropomyosin; TAS:UniProtKB.
DR   GO; GO:0001725; C:stress fiber; IDA:MGI.
DR   GO; GO:0051015; F:actin filament binding; IBA:GO_Central.
DR   GO; GO:0007015; P:actin filament organization; IBA:GO_Central.
DR   GO; GO:0006936; P:muscle contraction; IBA:GO_Central.
DR   FunFam; 1.20.5.170:FF:000005; Tropomyosin alpha-1 chain; 1.
DR   FunFam; 1.20.5.170:FF:000001; Tropomyosin alpha-1 chain isoform 1; 1.
DR   FunFam; 1.20.5.340:FF:000001; Tropomyosin alpha-1 chain isoform 2; 1.
DR   Gene3D; 1.20.5.170; -; 2.
DR   Gene3D; 1.20.5.340; -; 1.
DR   InterPro; IPR000533; Tropomyosin.
DR   PANTHER; PTHR19269; TROPOMYOSIN; 1.
DR   Pfam; PF00261; Tropomyosin; 1.
DR   PRINTS; PR00194; TROPOMYOSIN.
DR   SUPFAM; SSF57997; Tropomyosin; 1.
DR   PROSITE; PS00326; TROPOMYOSIN; 1.
DR   neXtProt; NX_P06753; -.
DR   PharmGKB; PA36692; -.
DR   TreeFam; TF351519; -.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Actin-binding; Alternative splicing;
KW   Chromosomal rearrangement; Coiled coil; Cytoplasm; Cytoskeleton;
KW   Direct protein sequencing; Disease variant; Muscle protein;
KW   Nemaline myopathy; Phosphoprotein; Proteomics identification;
KW   Proto-oncogene; Reference proteome.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:P58776"
FT   CHAIN           2..285
FT                   /note="Tropomyosin alpha-3 chain"
FT                   /id="PRO_0000205632"
FT   REGION          16..44
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          1..285
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        16..41
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         2
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000250|UniProtKB:P58776"
FT   MOD_RES         54
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P07951"
FT   MOD_RES         62
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P58774"
FT   MOD_RES         88
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         109
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P07951"
FT   MOD_RES         207
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P07951"
FT   MOD_RES         216
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P58775"
FT   MOD_RES         253
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P07951"
FT   MOD_RES         262
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P58775"
FT   MOD_RES         272
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P21107"
FT   MOD_RES         283
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P07951"
FT   MOD_RES         284
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P21107"
FT   VAR_SEQ         1..127
FT                   /note="Missing (in isoform 7)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_054792"
FT   VAR_SEQ         1..81
FT                   /note="MMEAIKKKMQMLKLDKENALDRAEQAEAEQKQAEERSKQLEDELAAMQKKLK
FT                   GTEDELDKYSEALKDAQEKLELAEKKAAD -> MAGITTIEAVKRKIQVLQQQADDAEE
FT                   RAERLQREVEGERRAREQ (in isoform 2, isoform 3 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:3024106"
FT                   /id="VSP_006604"
FT   VAR_SEQ         1..2
FT                   /note="MM -> MAGITTI (in isoform 4 and isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_047302"
FT   VAR_SEQ         5..21
FT                   /note="IKKKMQMLKLDKENALD -> VKRKIQVLQQQADDAEE (in isoform 4
FT                   and isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_047303"
FT   VAR_SEQ         25..81
FT                   /note="QAEAEQKQAEERSKQLEDELAAMQKKLKGTEDELDKYSEALKDAQEKLELAE
FT                   KKAAD -> RLQREVEGERRAREQ (in isoform 4 and isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_047304"
FT   VAR_SEQ         190..212
FT                   /note="KCSELEEELKNVTNNLKSLEAQA -> RCREMDEQIRLMDQNLKCLSAAE
FT                   (in isoform 2, isoform 3 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:3024106"
FT                   /id="VSP_006605"
FT   VAR_SEQ         259..285
FT                   /note="DELYAQKLKYKAISEELDHALNDMTSI -> ERLYSQLERNRLLSNELKLTL
FT                   HDLCD (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_006607"
FT   VAR_SEQ         259..260
FT                   /note="DE -> ER (in isoform 4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_047305"
FT   VAR_SEQ         260..285
FT                   /note="ELYAQKLKYKAISEELDHALNDMTSI -> KLKCTKEEHLCTQRMLDQTLLD
FT                   LNEM (in isoform 2, isoform 5 and isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:3024106"
FT                   /id="VSP_006606"
FT   VAR_SEQ         263..285
FT                   /note="AQKLKYKAISEELDHALNDMTSI -> SQLERNRLLSNELKLTLHDLCD
FT                   (in isoform 4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_047306"
FT   VARIANT         4
FT                   /note="A -> V (in CMYO4A; dbSNP:rs199474711)"
FT                   /evidence="ECO:0000269|PubMed:19953533"
FT                   /id="VAR_071499"
FT   VARIANT         9
FT                   /note="M -> R (in CMYO4A; decrease in the sensitivity of
FT                   contraction to activating calcium; dbSNP:rs80358247)"
FT                   /evidence="ECO:0000269|PubMed:10587521,
FT                   ECO:0000269|PubMed:7704029"
FT                   /id="VAR_013460"
FT   VARIANT         88
FT                   /note="S -> F (in CMYO4A)"
FT                   /evidence="ECO:0000269|PubMed:24692096"
FT                   /id="VAR_071500"
FT   VARIANT         91
FT                   /note="R -> C (found in patients with undefined congenital
FT                   myopathy; likely pathogenic; dbSNP:rs1571418855)"
FT                   /evidence="ECO:0000269|PubMed:24692096"
FT                   /id="VAR_071501"
FT   VARIANT         91
FT                   /note="R -> P (in CMYO4A; dbSNP:rs199474713)"
FT                   /evidence="ECO:0000269|PubMed:19953533"
FT                   /id="VAR_071502"
FT   VARIANT         100
FT                   /note="L -> M (in CMYO4A; dbSNP:rs121964853)"
FT                   /evidence="ECO:0000269|PubMed:18300303"
FT                   /id="VAR_070066"
FT   VARIANT         100
FT                   /note="L -> V (in CMYO4A; dbSNP:rs121964853)"
FT                   /evidence="ECO:0000269|PubMed:24692096"
FT                   /id="VAR_071503"
FT   VARIANT         149
FT                   /note="L -> I (in CMYO4A)"
FT                   /evidence="ECO:0000269|PubMed:24239060"
FT                   /id="VAR_071504"
FT   VARIANT         151
FT                   /note="E -> A (in CMYO4A)"
FT                   /evidence="ECO:0000269|PubMed:24692096"
FT                   /id="VAR_071505"
FT   VARIANT         168
FT                   /note="R -> C (in CMYO4A; also found in patients with
FT                   undefined congenital myopathy; dbSNP:rs121964854)"
FT                   /evidence="ECO:0000269|PubMed:18300303,
FT                   ECO:0000269|PubMed:19487656, ECO:0000269|PubMed:24692096"
FT                   /id="VAR_070067"
FT   VARIANT         168
FT                   /note="R -> G (in CMYO4A; dbSNP:rs121964854)"
FT                   /evidence="ECO:0000269|PubMed:18300303"
FT                   /id="VAR_070068"
FT   VARIANT         168
FT                   /note="R -> H (in CMYO4A; also found in patients with
FT                   undefined congenital myopathy; dbSNP:rs121964852)"
FT                   /evidence="ECO:0000269|PubMed:17376686,
FT                   ECO:0000269|PubMed:18300303, ECO:0000269|PubMed:19553118,
FT                   ECO:0000269|PubMed:19953533, ECO:0000269|PubMed:20951040,
FT                   ECO:0000269|PubMed:24692096"
FT                   /id="VAR_070069"
FT   VARIANT         169
FT                   /note="K -> E (in CMYO4A; dbSNP:rs199474715)"
FT                   /evidence="ECO:0000269|PubMed:18300303"
FT                   /id="VAR_070070"
FT   VARIANT         174
FT                   /note="E -> A (in CMYO4A; dbSNP:rs199474716)"
FT                   /evidence="ECO:0000269|PubMed:20951040"
FT                   /id="VAR_071506"
FT   VARIANT         241
FT                   /note="E -> K (in CMYO4A; dbSNP:rs199474717)"
FT                   /evidence="ECO:0000269|PubMed:19953533"
FT                   /id="VAR_071507"
FT   VARIANT         245
FT                   /note="R -> G (in CMYO4A; dbSNP:rs199474718)"
FT                   /evidence="ECO:0000269|PubMed:18300303"
FT                   /id="VAR_070071"
FT   VARIANT         245
FT                   /note="R -> I (in CMYO4A; dbSNP:rs797046047)"
FT                   /evidence="ECO:0000269|PubMed:24692096"
FT                   /id="VAR_071508"
FT   VARIANT         253
FT                   /note="T -> K (found in patients with undefined congenital
FT                   myopathy; likely pathogenic; dbSNP:rs1553248515)"
FT                   /evidence="ECO:0000269|PubMed:24692096"
FT                   /id="VAR_071509"
FT   CONFLICT        150
FT                   /note="K -> E (in Ref. 13; CAA27243)"
FT                   /evidence="ECO:0000305"
FT   HELIX           44..110
FT                   /evidence="ECO:0007829|PDB:6OTN"
FT   INIT_MET        P06753-2:1
FT                   /note="Removed"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         P06753-2:2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         P06753-2:177
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         P06753-2:215
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   CONFLICT        P06753-2:33
FT                   /note="R -> Q (in Ref. 8; ABC40673)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        P06753-2:43
FT                   /note="E -> K (in Ref. 8; ABC40673)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        P06753-2:66
FT                   /note="A -> P (in Ref. 8; ABC40673)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        P06753-2:85
FT                   /note="D -> G (in Ref. 8; ABC40673)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        P06753-2:110
FT                   /note="I -> L (in Ref. 8; ABC40673)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        P06753-2:135
FT                   /note="I -> T (in Ref. 8; ABC40673)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        P06753-2:150
FT                   /note="A -> T (in Ref. 8; ABC40673)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        P06753-2:192
FT                   /note="L -> F (in Ref. 8; ABC40673)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        P06753-2:196
FT                   /note="L -> P (in Ref. 8; ABC40673)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        P06753-2:202
FT                   /note="R -> C (in Ref. 8; ABC40673)"
FT                   /evidence="ECO:0000305"
FT   INIT_MET        P06753-3:1
FT                   /note="Removed"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         P06753-3:2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         P06753-3:177
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         P06753-5:215
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         P06753-6:177
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         P06753-7:125
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
SQ   SEQUENCE   285 AA;  32950 MW;  99EAD24C45460A14 CRC64;
     MMEAIKKKMQ MLKLDKENAL DRAEQAEAEQ KQAEERSKQL EDELAAMQKK LKGTEDELDK
     YSEALKDAQE KLELAEKKAA DAEAEVASLN RRIQLVEEEL DRAQERLATA LQKLEEAEKA
     ADESERGMKV IENRALKDEE KMELQEIQLK EAKHIAEEAD RKYEEVARKL VIIEGDLERT
     EERAELAESK CSELEEELKN VTNNLKSLEA QAEKYSQKED KYEEEIKILT DKLKEAETRA
     EFAERSVAKL EKTIDDLEDE LYAQKLKYKA ISEELDHALN DMTSI
//
